Literature DB >> 2049246

Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.

R V Lewis1, L E Ramsay, P R Jackson, W W Yeo, M S Lennard, G T Tucker.   

Abstract

1. The effects of single doses of metoprolol 50 mg, metoprolol 100 mg and atenolol 100 mg on exercise tolerance were compared with placebo in a double-blind random cross-over study in 12 healthy subjects. Nine subjects were extensive metabolisers of debrisoquine, and three were poor metabolisers. 2. Three hours after dosing beta-adrenoceptor blocker treatments significantly reduced exercise heart rate, prolonged time to complete exercise, and increased subjective fatigue measured by visual analogue scale. 3. Scores for subjective fatigue did not correlate with reduction in exercise heart rate or prolongation of exercise time. Exercise time prolongation was weakly but not significantly correlated with exercise heart rate reduction. 4. When compared with placebo, prolongation of exercise time and increased fatigue with metoprolol were not significantly related to debrisoquine oxidation phenotype or to the debrisoquine/4-hydroxydebrisoquine (D/4OH-D) ratio. 5. When metoprolol responses were compared with those for atenolol, changes in exercise time and fatigue scores were significantly related to oxidation phenotype. For metoprolol 100 mg, poor metabolisers required 20.8 s longer to complete exercise (P less than 0.05) and had higher fatigue scores by 78% (P less than 0.05) as compared with extensive metabolisers.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049246      PMCID: PMC1368323          DOI: 10.1111/j.1365-2125.1991.tb05551.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

Review 1.  Beta blockers and fatigue.

Authors:  P E Hall; M J Kendall; S R Smith
Journal:  J Clin Hosp Pharm       Date:  1984-12

2.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

3.  Adverse effects from metoprolol are not generally associated with oxidation status.

Authors:  D W Clark; A K Morgan; H Waal-Manning
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

4.  The effect of beta-adrenoceptor blockade on factors affecting exercise tolerance in normal man.

Authors:  S B Pearson; D C Banks; J M Patrick
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

5.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

6.  Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.

Authors:  F Wagner; E Jähnchen; D Trenk; M Eichelbaum; P Harnasch; G Hauf; H Roskamm
Journal:  Klin Wochenschr       Date:  1987-12-15

7.  Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.

Authors:  R V Lewis; M S Lennard; P R Jackson; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

8.  Variability in the pharmacokinetics of atenolol and metoprolol.

Authors:  H Ledermann; H Bippi; H Boekens; J C Frölich; H Herrmann; K Schmitt-Landherr
Journal:  Arzneimittelforschung       Date:  1985

9.  Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.

Authors:  D W Clark; I R Edwards
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

10.  Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients.

Authors:  J H Silas; S Freestone; M S Lennard; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

View more
  4 in total

1.  CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

Authors:  Jasmine A Luzum; Kevin M Sweet; Philip F Binkley; Tara J Schmidlen; Joseph P Jarvis; Michael F Christman; Wolfgang Sadee; Joseph P Kitzmiller
Journal:  Pharm Res       Date:  2017-02-08       Impact factor: 4.200

Review 2.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 3.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

4.  Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.

Authors:  M A Laurent-Kenesi; C Funck-Brentano; J M Poirier; D Decolin; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.